F18.14
Inhalant abuse with inhalant-induced mood disorder
Clinical Classification Guidelines
Inclusion Terms
- Inhalant use disorder, mild, with inhalant induced depressive disorder
Medical Intelligence & Overview
Inhalant abuse with inhalant-induced mood disorder, classified under ICD-10 code F18.14, involves the misuse of substances that are inhaled to achieve psychoactive effects, leading to mood disturbances. This condition reflects both the harmful pattern of inhalant use and the psychological impact, particularly the development of depressive symptoms directly linked to inhalant consumption. Recognizing this disorder is essential for understanding its effects on mental health and guiding appropriate treatment strategies.
Causes & Symptoms
Clinical Causes: Repeated inhalation of volatile substances such as solvents, aerosols, gases, or nitrites. Psychological factors such as curiosity, peer influence, or attempts to self-medicate underlying mental health issues. Environmental exposure and easy availability of inhalants, especially in younger populations. History of substance use disorder or previous misuse of psychoactive substances. Socioeconomic factors, including stress, trauma, or lack of access to mental health resources.
Key Symptoms: Depressive mood, which may include feelings of sadness, hopelessness, or irritability. Dizziness or lightheadedness during or following inhalation episodes. Impaired judgment or coordination while under the influence. Withdrawal from social activities or increased isolation. Changes in sleep patterns, such as insomnia or hypersomnia. Decreased motivation and reduced interest in previous pleasurable activities. Physical signs like headaches, nausea, or dizziness.
Diagnostic & Treatment
Diagnosis Path: Diagnosing inhalant abuse with mood disorder involves a comprehensive clinical assessment that includes detailed history-taking about inhalant use, evaluation of mental health symptoms, and ruling out other possible causes of mood disturbances. Healthcare providers may utilize tools such as screening questionnaires and standardized diagnostic interviews. Physical examinations and laboratory tests can help identify signs of inhalant exposure, while psychological assessments help determine the severity and impact of mood symptoms.
Treatment Protocols: Cessation support for inhalant use through counseling and behavioral therapy. Psychotherapy modalities such as cognitive-behavioral therapy (CBT) to address depressive symptoms and underlying issues. Medications may be considered to manage mood symptoms, although their use should be closely monitored by healthcare professionals. Provision of social support and education to prevent relapse and promote healthier behaviors. Monitoring for potential complications or co-occurring mental health disorders. In some cases, inpatient or outpatient programs may be appropriate depending on the severity of inhalant use and mood disorder.
Clinical Advice & FAQs
Billing Guidance
Is F18.14 a billable ICD-10 code?
Yes, F18.14 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F18.14?
Clinical documentation must specify the nature of Inhalant abuse with inhalant-induced mood disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
